Skip to main content

Day: August 15, 2024

Interim results for the period ended June 30, 2024

Highlights and subsequent events Golar LNG Limited (“Golar” or “the Company”) signed an agreement for a 20-year FLNG deployment in Argentina. Strong progress on further FLNG opportunities. Golar and bp entered into commercial reset arrangements for FLNG Gimi for the pre-Commercial Operations Date (“Pre-COD”) period, enabling refinancing at improved terms which is expected to release liquidity of up to $0.5 billion. Finalization of yard EPC and payment terms agreed in preparation for contracting of 3.5mtpa MKII FLNG. Golar reports Q2 2024 (“Q2” or “the quarter”) Net income attributable to Golar of $26 million, and Adjusted EBITDA1 of $59 million. Adjusted EBITDA backlog1 of approximately $11 billion, including existing and redeployment charters for FLNGs Hilli and Gimi, before commodity exposure. FLNG Hilli Episeyo maintains market leading...

Continue reading

JD.com Announces Second Quarter and Interim 2024 Results

BEIJING, Aug. 15, 2024 (GLOBE NEWSWIRE) — JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), the “Company”), a leading supply chain-based technology and service provider, today announced its unaudited financial results for the three and six months ended June 30, 2024. Second Quarter 2024 HighlightsNet revenues were RMB291.4 billion (US$140.1 billion) for the second quarter of 2024, an increase of 1.2% from the second quarter of 2023. Income from operations was RMB10.5 billion (US$1.4 billion) for the second quarter of 2024, compared to RMB8.3 billion for the second quarter of 2023. Non-GAAP2 income from operations was RMB11.6 billion (US$1.6 billion) for the second quarter of 2024, compared to RMB8.7 billion for the second quarter of 2023. Operating margin of JD Retail before unallocated items was...

Continue reading

Digihost Announces 57% Increase in Quarterly-YOY Revenue for Q2 2024 and $8M EBITDA* for YTD 2024

HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (Nasdaq / TSXV: DGHI), an innovative U.S. based blockchain technology and computer infrastructure company, is pleased to provide a summary of the Company’s unaudited financial results for the second quarter ended June 30, 2024 (all amounts in U.S. dollars, unless otherwise indicated) and a 2024 year-to-date update on its operations. The Company’s unaudited consolidated financial statements and management’s discussion and analysis (“MD&A”) for the six-month period ended June 30, 2024 have been filed and made accessible under the Company’s continuous disclosure profile on SEDAR+ at www.sedarplus.ca and also on EDGAR at www.sec.gov/edgar. Comparative Financial Highlights for the Three-Month Period Ended June 30, 2024:Revenue of...

Continue reading

Avance Gas Holding Ltd: Sells its VLGC fleet for $1,050 million to BW LPG Ltd with expected gain on sale of approximately $315 million

Hamilton, Bermuda August 15, 2024 Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) has on August 15, 2024, entered into an agreement with BW LPG Ltd (“BW LPG” or “the Buyer”) to sell its fleet of Very Large Gas Carriers (VLGC) for a consideration of $1,050 million. The Avance Gas VLGC fleet today consist of eight 2015 built eco VLGCs and four dual fuelled VLGCs built 2022 and 2023. The transaction is regulated by 10 individual Memorandum of Agreement (MoA) for the 10 owned VLGCs while the remaining two VLGCs on sale-leaseback agreement (SLB) is agreed to be novated with the existing debt obligation. The transactions and delivery of ships to the Buyer is scheduled to take place in the window September 15 to December 31, 2024, which enables a smooth handover while allowing Avance Gas to trade the ships for some further period...

Continue reading

Interim report – second quarter of 2024

Thursday, Schouw & Co. released its interim report for the second quarter of 2024; As expected, consolidated revenue for Q2 2024 was down on the year before, driven by a drop in volume sales combined with lower prices. EBITDA, on the other hand, increased significantly with BioMar as the main contributor. Cash flows from operations were kept on a high level. HighlightsDKK 8.7bn revenue – a reduction of 5% DKK 737m EBITDA – an increase of 11% DKK 373m cash flows from operations – an reduction of DKK 11m DKK 10.52 earnings per share – an increase of 14% 13.8% ROIC excluding goodwill – an increase of 2.5 ppStatement by Jens Bjerg Sørensen, President of Schouw & Co. – Overall, Q2 2024 was a very strong quarter for Schouw & Co. Particularly BioMar, which is one of the world’s leading manufacturers of quality feed for...

Continue reading

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) — ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human Klotho gene, referred to as “s-KL”, for the treatment of cognitive and neurodegenerative diseases. The human Klotho gene, sometimes referred to as the “anti-aging” gene, also controls many normal brain and neurologic functions. The Klotho gene-therapy patent in the U.S. is instrumental new intellectual property (“IP”) protecting...

Continue reading

Li Auto Inc. to Report Second Quarter 2024 Financial Results on August 28, 2024

BEIJING, China, Aug. 15, 2024 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it will report its unaudited financial results for the second quarter of 2024 before the U.S. market opens on Wednesday, August 28, 2024. The Company’s management will hold an earnings conference call on Wednesday, August 28, 2024, at 8:00 A.M. U.S. Eastern Time or 8:00 P.M. Beijing/Hong Kong Time on the same day. For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time. Upon registration, participants will receive the conference call access information, including dial-in numbers, passcode, and a unique access PIN. To join the conference, please dial the number...

Continue reading

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

The approvals process is anticipated to be completed in the third quarter of 2025Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025. “EMA acceptance takes us a step closer to making AVT06 available in Europe, which is good news for patients and caregivers,” said Joseph McClellan, Chief Scientific Officer of Alvotech....

Continue reading

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

The approvals process is anticipated to be completed in the third quarter of 2025REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025. “EMA acceptance takes us a step closer to making AVT06 available in Europe, which is good news for patients and caregivers,”...

Continue reading

DFDS SHARES PURCHASED BY CFO

COMPANY ANNOUNCEMENT no. 62 – 15 August 2024 Yesterday, Karen Dyrskjøt Boesen, CFO, purchased 5,440 DFDS A/S shares. Pursuant to Article 19 (3) of Regulation (EU) no. 596/2014 (Market Abuse Regulation), DFDS A/S is required disclose information regarding transactions in DFDS A/S’ shares by persons discharging managerial responsibilities and persons closely associated with them. Transaction details are reported in the attachment.Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59About DFDS We operate a transport network in and around Europe with an annual revenue of DKK 28bn and 14,000 full-time employees. We move goods in trailers by ferry, road & rail, and we offer complementary and related transport and logistics solutions. We also move car and foot passengers on short sea and overnight ferry routes. DFDS was...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.